BBS1 — Bardet-Biedl syndrome 1

The BBS1 gene provides instructions for making a protein that is a crucial part of a tiny, hair-like structure on the surface of cells called a cilium. Cilia act like cellular antennas, sensing the environment and sending signals that help the body develop and function properly. In the eyes, these structures are especially important for the light-sensing cells (photoreceptors) to maintain their shape and process light into vision. The BBS1 protein works together with other proteins to form a complex that acts like a delivery truck, transporting essential materials up and down the cilium. When the BBS1 gene is mutated, the delivery system in the cilia breaks down. In the eyes, this means the light-sensing cells don't get the materials they need to survive, leading to a gradual loss of vision, starting with night blindness and often progressing to severe visual impairment. Because cilia are found all over the body, these mutations also cause problems in other organs, leading to a condition called Bardet-Biedl syndrome (BBS). People with BBS may experience obesity, extra fingers or toes, kidney problems, and learning difficulties, though the exact symptoms can vary from person to person. BBS1-related disorders are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene—one from each parent—to develop the condition. The parents, who usually have only one mutated copy, are called carriers. Carriers typically do not show any symptoms of the disease. If both parents are carriers, there is a 25% chance with each pregnancy of having a child with the condition. Genetic testing can help confirm a diagnosis and provide important information for family planning.

Gene description: BBS1 encodes a component of the BBSome, a protein complex essential for cilia formation and function, involved in Bardet-Biedl syndrome.

Patient and family guide: The BBS1 gene provides instructions for making a protein that is a crucial part of a tiny, hair-like structure on the surface of cells called a cilium. Cilia act like cellular antennas, sensing the environment and sending signals that help the body develop and function properly. In the eyes, these structures are especially important for the light-sensing cells (photoreceptors) to maintain their shape and process light into vision. The BBS1 protein works together with other proteins to form a complex that acts like a delivery truck, transporting essential materials up and down the cilium. When the BBS1 gene is mutated, the delivery system in the cilia breaks down. In the eyes, this means the light-sensing cells don't get the materials they need to survive, leading to a gradual loss of vision, starting with night blindness and often progressing to severe visual impairment. Because cilia are found all over the body, these mutations also cause problems in other organs, leading to a condition called Bardet-Biedl syndrome (BBS). People with BBS may experience obesity, extra fingers or toes, kidney problems, and learning difficulties, though the exact symptoms can vary from person to person. BBS1-related disorders are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene—one from each parent—to develop the condition. The parents, who usually have only one mutated copy, are called carriers. Carriers typically do not show any symptoms of the disease. If both parents are carriers, there is a 25% chance with each pregnancy of having a child with the condition. Genetic testing can help confirm a diagnosis and provide important information for family planning.

Gene function: BBS1 is crucial for the proper functioning of photoreceptor cells in the retina. It plays a role in the transport of proteins to the outer segments of rods and cones, which are specialized structures responsible for light perception. Dysfunction of BBS1 disrupts ciliary processes vital for photoreceptor maintenance and survival, leading to progressive retinal degeneration and vision loss characteristic of IRDs.

Protein structure: The BBS1 gene encodes a protein of 593 amino acids with a molecular weight of approximately 65 kDa. While the exact high-resolution crystal structure of the entire human BBS1 protein has not been fully resolved, structural predictions and studies of homologous proteins indicate that it contains a beta-propeller domain at its N-terminus. This domain is a common structural motif involved in mediating protein-protein interactions, which is consistent with BBS1's role as a core scaffolding component of the BBSome complex. BBS1 does not function in isolation; it assembles with seven other BBS proteins (BBS2, BBS4, BBS5, BBS7, BBS8, BBS9, and BBS18) to form the stable, octameric BBSome complex. Within this complex, BBS1 is thought to interact directly with several other subunits, including BBS2 and BBS7, helping to maintain the structural integrity of the entire assembly. Furthermore, BBS1 contains specific binding motifs that allow the BBSome to interact with the ARL6 (BBS3) GTPase, which is required for the recruitment of the BBSome to the ciliary membrane, and with the intraflagellar transport (IFT) machinery for movement along the cilium.

Molecular function: The BBS1 gene encodes a core component of the BBSome, a highly conserved, octameric protein complex (consisting of BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, BBS9, and BBS18) that is essential for the proper function of primary cilia. The primary role of the BBSome is to act as a specialized coat complex that regulates the trafficking of proteins, particularly membrane receptors, into and out of the ciliary compartment. This transport is crucial because the cilium lacks protein synthesis machinery and relies entirely on the targeted delivery of structural and signaling molecules from the cell body. At the molecular level, BBS1 is thought to be a key interacting subunit that helps link the BBSome to the intraflagellar transport (IFT) machinery, specifically the IFT-B complex, which drives the movement of cargo along the ciliary axoneme. In the retina, the BBSome is vital for the transport of phototransduction cascade proteins, such as rhodopsin, from the inner segment through the connecting cilium to the outer segment of photoreceptor cells. Disruption of BBS1 impairs this transport, leading to the accumulation of proteins in the inner segment, structural degradation of the outer segment, and eventual photoreceptor cell death. Furthermore, the BBSome is involved in regulating key cellular signaling pathways, including Sonic Hedgehog (Shh) and Wnt signaling, which are critical for development and tissue homeostasis.

Expression pattern: The BBS1 gene is ubiquitously expressed across a wide range of human tissues, reflecting its fundamental role in the function of primary cilia, which are present on almost all cell types. High levels of expression are found in the retina, particularly within the photoreceptor cells (both rods and cones), where the protein is localized to the connecting cilium and inner segment. This localization is critical for the massive daily transport of proteins required for the maintenance and function of the photoreceptor outer segments. In addition to the retina, significant BBS1 expression is observed in the brain, including the hypothalamus, which correlates with the obesity and cognitive phenotypes seen in Bardet-Biedl syndrome. It is also highly expressed in the kidneys, particularly in the epithelial cells of the renal tubules, as well as in the olfactory epithelium, testes, and developing limb buds. The broad expression pattern underscores the multisystemic nature of the disease when the gene is mutated.

Mutation spectrum: The mutation spectrum of the BBS1 gene is diverse, encompassing over 100 known pathogenic variants. These include missense, nonsense, frameshift (insertions and deletions), and splice-site mutations. Missense mutations are the most common type, often affecting highly conserved amino acid residues critical for the structural integrity of the BBS1 protein or its interaction with other BBSome subunits. Large genomic deletions or duplications are relatively rare but have been reported. A significant feature of the BBS1 mutation spectrum is the presence of a major hotspot or founder mutation: the c.1169T>G transition, which results in the p.Met390Arg (M390R) amino acid substitution. This specific variant accounts for approximately 70-80% of all pathogenic BBS1 alleles in populations of European descent. The high prevalence of this single mutation makes targeted screening for M390R a common first step in the genetic diagnosis of suspected Bardet-Biedl syndrome in these populations. Other mutations are generally private or found in specific isolated populations.

Pathogenic variants: 1. p.Met390Arg (c.1169T>G) - The most common pathogenic variant, accounting for up to 80% of BBS1 alleles in European populations; associated with classic Bardet-Biedl syndrome. 2. p.Glu549* (c.1645G>T) - A nonsense mutation leading to premature protein truncation; typically associated with a severe, early-onset multisystem phenotype. 3. p.Arg275* (c.823C>T) - Another relatively common nonsense mutation that results in a loss of function and classic BBS features. 4. c.432+1G>A - A canonical splice site mutation that disrupts normal mRNA splicing, leading to an aberrant or absent protein product. 5. p.Gly144Arg (c.430G>A) - A missense mutation that impairs BBSome assembly; has been reported in patients with both syndromic BBS and non-syndromic retinitis pigmentosa.

Clinical significance: Mutations in the BBS1 gene are the most common cause of Bardet-Biedl syndrome (BBS), accounting for approximately 20-25% of all cases. BBS is a pleiotropic, autosomal recessive ciliopathy characterized by a wide spectrum of clinical features. The hallmark manifestation is progressive retinal dystrophy, typically presenting as atypical retinitis pigmentosa or cone-rod dystrophy. Patients often experience night blindness in early childhood, followed by progressive loss of peripheral vision, color vision defects, and eventual decline in central visual acuity, frequently leading to legal blindness by the second or third decade of life. Beyond the ocular phenotype, BBS1 mutations cause significant systemic manifestations. These include early-onset truncal obesity, postaxial polydactyly (extra digits on the hands or feet), hypogonadism or genital anomalies, and variable degrees of cognitive impairment or learning disabilities. Renal anomalies are also a critical component of the syndrome, ranging from structural defects like cystic dysplasia to progressive chronic kidney disease, which is a major cause of morbidity and mortality in these patients. The severity and age of onset of these features can vary widely, even among individuals with the same genetic variants.

Inheritance: Autosomal Recessive

Chromosomal location: 11q13.2

Genotype-phenotype correlations: Genotype-phenotype correlations in BBS1-related Bardet-Biedl syndrome can be complex due to the variable expressivity of the disease. However, some general trends have been observed. The most common missense mutation, p.Met390Arg (M390R), is often associated with a slightly milder or more classic presentation of BBS compared to truncating mutations (nonsense or frameshift), which tend to cause a more severe phenotype with earlier onset of retinal degeneration and more pronounced systemic features. Interestingly, some patients with specific BBS1 mutations, particularly certain missense variants, may present with non-syndromic retinitis pigmentosa or a very mild form of BBS where the systemic features are subtle or absent. This suggests that some variants may retain partial BBSome function that is sufficient for normal development in most tissues but inadequate for the high demands of photoreceptor maintenance. Additionally, the presence of modifying alleles in other BBS genes (digenic or triallelic inheritance) can influence the severity and specific manifestations of the disease in some individuals.

Research and therapeutic approaches: Currently, there are no FDA-approved disease-modifying therapies specifically for BBS1-related Bardet-Biedl syndrome. Management is primarily supportive and multidisciplinary, focusing on treating the symptoms. This includes regular ophthalmologic monitoring, use of low-vision aids, aggressive management of obesity and metabolic complications (such as diabetes and hyperlipidemia) through diet and exercise, and close monitoring of renal function. In some cases, targeted therapies for specific complications, such as setmelanotide (an MC4R agonist) for BBS-associated obesity, have shown promise and received regulatory approval for weight management in these patients. However, significant progress is being made in the development of targeted genetic therapies. Adeno-associated virus (AAV)-mediated gene augmentation therapy is a leading approach, aiming to deliver a functional copy of the BBS1 gene to the affected tissues, particularly the retina. Preclinical studies in Bbs1 mutant mouse models have demonstrated that subretinal injection of AAV-BBS1 can successfully rescue BBSome assembly, preserve photoreceptor structure, and improve retinal function. Based on these promising results, clinical trials are advancing. For example, Axovia Therapeutics is developing AXV-101, an AAV9-based gene therapy specifically targeting BBS1-related retinal degeneration, with first-in-human clinical trials (e.g., NCT07269665) designed to assess safety and preliminary efficacy. Other approaches, such as antisense oligonucleotides (ASOs) or read-through drugs for specific mutation types, are also being explored in preclinical settings.

Diagnostic testing: Diagnostic testing for BBS1 mutations typically involves targeted gene panels for inherited retinal diseases (IRDs) or comprehensive ciliopathy panels. These panels use next-generation sequencing (NGS) to detect single nucleotide variants, small insertions/deletions, and sometimes larger copy number variations within the BBS1 gene and other BBS-associated genes. If panel testing is inconclusive, whole exome sequencing (WES) or whole genome sequencing (WGS) may be employed to identify rare or novel variants, including deep intronic mutations that affect splicing. Genetic counseling is a crucial component of the diagnostic process. Since BBS is an autosomal recessive condition, parents of an affected individual are typically obligate carriers and have a 25% chance of having another affected child in each subsequent pregnancy. Carrier testing for at-risk family members and prenatal or preimplantation genetic testing can be offered once the specific pathogenic variants in a family have been identified. Counselors also play a vital role in educating families about the multisystem nature of the disease and coordinating multidisciplinary care.

Animal models: Mouse models have been extensively used to study BBS1 function and disease mechanisms. Homozygous Bbs1 knockout mice (Bbs1-/-) display partial embryonic lethality, low body weight before weaning, followed by significant obesity after weaning. They also exhibit retinal degeneration, abnormal olfactory epithelium, and male infertility. These models have revealed that BBS1 is essential for the formation and function of primary cilia, and its loss leads to defects in ciliary protein trafficking. Another important model is the Bbs1 M390R knock-in mouse, which carries the most common human pathogenic variant. This model closely recapitulates the human Bardet-Biedl syndrome phenotype, including progressive photoreceptor degeneration, obesity, and structural brain anomalies. Studies in these mice have demonstrated that the M390R mutation disrupts the BBSome complex assembly and function, leading to mislocalization of key signaling proteins in the retina and other tissues. Zebrafish models have also been utilized, particularly for rapid screening of novel variants and studying the developmental aspects of ciliogenesis and early retinal formation.

Population genetics: The carrier frequency of BBS1 mutations varies significantly by population, largely driven by the prevalence of the p.Met390Arg (M390R) founder mutation. In populations of Northern European descent, the carrier frequency for the M390R variant is estimated to be approximately 1 in 250 to 1 in 300. This makes BBS1 the most common genetic cause of Bardet-Biedl syndrome in these regions. In contrast, the mutation is rare or absent in Asian and African populations. Certain isolated or consanguineous populations may have higher carrier frequencies of specific, private BBS1 mutations due to founder effects and genetic drift. For example, specific variants have been identified at higher frequencies in certain Middle Eastern and North African communities.

Selected references: 1. Mykytyn K, et al. Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. Nat Genet, 2002. PMID: 12172546 2. Nachury MV, et al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. Cell, 2007. PMID: 17574030 3. Estrada-Cuzcano A, et al. BBS1 mutations in a wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa to Bardet-Biedl syndrome. Arch Ophthalmol, 2012. PMID: 23143442 4. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet, 2013. PMID: 23249954 5. Seo S, et al. Subretinal gene therapy of mice with Bardet-Biedl syndrome type 1. Invest Ophthalmol Vis Sci, 2013. PMID: 23900607 6. Weihbrecht K, et al. Keeping an Eye on Bardet-Biedl Syndrome: A Comprehensive Review of the Role of Bardet-Biedl Syndrome Genes in the Eye. Med Res Arch, 2017. PMID: 29546237 7. Niederlova V, et al. Bardet-Biedl syndrome: a review of the clinical, genetic, and molecular landscape. Clin Genet, 2019. PMID: 31436321